中國生物製藥(01177.HK)獲口服COVID-19治療藥物內地獨家推廣權
中國生物製藥(01177.HK)公布,附屬正大天晴與平安鹽野義簽訂獨家市場推廣協議。據此,正大天晴獲授予新型冠狀病毒感染「COVID-19」治療藥物Ensitrelvir在中國的獨家市場推廣權,初步為期五年。
Ensitrelvir是一款新型口服COVID-19治療藥物,由北海道大學與鹽野義製藥株式會社共同研發。通過本次合作,正大天晴成為Ensitrelvir在中國的獨家市場推廣夥伴,將可儘早惠及內地患者,助力抗擊COVID-19疫情。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.